Results from Ultimovacs’ DOVACC phase II study confirm the termination of the UV1 program, in line with the previously communicated plan

▤ Summary

Zelluna says the UV1 cancer vaccine program is now finished after the DOVACC phase II study missed its primary endpoint. The company had already planned to wind down UV1, so this result confirms the end of that program. Zelluna will now keep its focus on the TCR-NK platform and its lead candidate ZI-MA4-1. The announcement also says the UV1 shutdown should not create any major additional costs beyond final study closure expenses.

▦ Linked Companies